NewsBenzingaGoodRx、製薬会社直接売上を2,977万3,000ドル過少計上したため、2026年第1四半期および第2四半期の財務情報はもはや信頼できないと発表 重大な内部統制の不備を予想 GoodRx、製薬会社直接売上を2,977万3,000ドル過少計上したため、2026年第1四半期および第2四半期の財務情報はもはや信頼できないと発表 重大な内部統制の不備を予想 Benzinga 2026.11.02 21:58 (GMT+0) Open on Benzinga Other news Jensen Huang Offers Nvidia Return If Board Wants Him Back Nvidia Tracks Seventh Weekly Loss Ahead of Earnings ‘You Don’t Want Rogue Agents’: Jamie Dimon Shuts Meta’s Muse AI Agent Out of JPMorgan. What It Means for META Stock. Investors Press for Answers From Nvidia, Where ‘Everything Has Changed’ Jensen Huang Signals Return to Nvidia CEO Role: Says Outpouring of Outside Support Is 'Stunning' Do Wall Street Analysts Like Diamondback Energy Stock?
‘You Don’t Want Rogue Agents’: Jamie Dimon Shuts Meta’s Muse AI Agent Out of JPMorgan. What It Means for META Stock.